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Summary 
AIMS OF THE STUDY: In our hospital, a previous attempt 
to introduce peripherally inserted central catheters 
(PICC) was aborted after a nonsystematic approach, 
seemingly accompanied by high rates of complications. 
The goal of this new interdisciplinary project was to in-
troduce PICCs in an academic hospital, with an embed-
ded interdisciplinary surveillance programme for both 
infectious and noninfectious outcomes. 
METHODS: We prospectively collected data for this sur-
veillance study from all patients who underwent PICC in-
sertion from 1 January 2014 and had the catheter re-
moved by 31 December 2015 in our 950-bed academic 
hospital (Bern University Hospital, Switzerland). Infec-
tious complications were defined according to Centers 
for Disease Control and Prevention / National 
Healthcare Safety Network criteria. PICCs were re-
stricted to cancer and infectious disease patients, and 
were followed up irrespective of the management set-
ting (inpatient, outpatient or intermittently hospitalised 
after insertion). An interdisciplinary team reviewed the 
outcomes on a routine basis and discussed changes to 
the process to improve outcomes, if necessary. 
RESULTS: One hundred and thirty-five PICCs were in-
serted in 124 patients, the majority of whom were pa-
tients from the medical oncology department (n = 107, 
86.3%). Indications for PICC insertion included: chemo-
therapy (n = 97, 71.9%), antibiotic therapy (n = 24, 
17.8%), total parenteral nutrition (n = 8, 5.9%), blood 
product transfusion (n = 4, 3.0%) and palliative care (n = 
2, 1.5%). During a total of 10 402 catheter-days (median 
dwell time 62 days), there were five central line-associ-
ated bloodstream infections, including one mucosal bar-
rier injury laboratory-confirmed bloodstream infection 
and two exit-site infections, yielding incidence rates of 
0.48 and 0.19 infections per 1000 catheter-days, respec-
tively. Incidence rates were 0.67 per 1000 catheter-days 
(n = 7) for radiologically documented deep venous 
thrombosis, 0.96 (n = 10) for tip dislocation and 0.67 (n 
= 7) for catheter occlusion. The overall rate of complica-
tions was 4.5 per 1000 catheter-days. Seventeen cathe-
ters (12.6%) were removed because of any complica-
tion. 
CONCLUSION: We successfully introduced PICCs in an 
academic hospital by implementing a systematic surveil-
lance programme for complications. Both infectious and 
noninfectious complications were rare. Infection pre-
vention specialists should be actively involved during the 
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introduction of new intravascular devices in order to 
provide quality indicators and assure patient safety. 
Key words: PICC; surveillance; introduction; CLABSI; in-
fectious complications; noninfectious complications 
Introduction 
Peripherally inserted central catheters (PICCs) are 
intravenous access lines inserted from a peripheral 
vein of the arm (usually basilic or cephalic vein), 
whose tips terminate in the inferior third of the vena 
cava at the junction with the right atrium. Their 
main indications are for the (outpatient) administra-
tion of chemotherapy, antibiotics and parenteral nu-
trition, and they may be used for therapies lasting a 
few days up to 12 months [1–3]. Since their intro-
duction in the late 1970s, the use of PICCs has 
steadily increased, especially in the oncology set-
ting [4], owing to a less invasive insertion technique 
(i.e. not requiring implantation or tunnelling) and a 
low rate of periprocedural mechanical complica-
tions, as well as a safe and easy removal technique 
[5, 6]. 
In contrast to those benefits, the safety of PICCs has 
occasionally been questioned because of the signif-
icant rate of complications occurring during cathe-
ter use, such as catheter-associated infection and 
thrombosis. 
The rate of infections varies according to patient 
characteristics, catheter-related factors and the dif-
ferent settings and standards of care [7–10]. This 
rate is reported as the number of bloodstream infec-
tions (according to a specific definition) per total 
number of catheter-days in place (commonly a de-
nominator of 1000 catheter days is used as standard) 
[11, 12]. A complicating factor, however, is that 
definitions differ between studies. Mucosal barrier 
injury laboratory-confirmed bloodstream infection 
(MBI-LCBI) is a new category that takes into ac-
count the fact that cancer patients may suffer blood-
stream infection from gut translocation while hav-
ing a central catheter in place (as opposed to true 
central line-associated bloodstream infection, 
CLABSI). However, the role of MBI-LCBI in sur-
veillance of PICC complications is unclear to date. 
For acute-care patients, both in and outside the in-
tensive care unit (ICU) setting, the bloodstream in-
fection rates are comparable to those associated 
with other central venous catheters [9, 10, 13, 14]. 
There is an increased risk of upper-extremity deep 
venous thrombosis associated with PICCs [15], for 
which reduced vein diameter with subsequent ve-
nous stasis and endothelial injury due to catheter 
displacement has been postulated as the main con-
tributing factor. There is conflicting evidence for 
high-risk patients, and newer data indicate a down-
ward trend in the number of thrombotic events [16–
18]. A correlation between the number of lumens 
and PICC-associated bloodstream infection and 
thrombosis is also well established [8, 9, 19]. 
Other complications including phlebitis, occlusion 
and mechanical problems (catheter tear or dislodg-
ment) are known to occur [6, 16] and, although not 
life-threatening, may require catheter removal. As 
described in prevention guidelines, targeted inter-
ventions including patient and staff education, and 
optimal PICC insertion practice and maintenance, 
as well as a multidisciplinary approach to imple-
mentation, currently seem the best strategy to 
achieve low rates of complications [3, 17, 20, 21]. 
Our goal was to introduce PICCs for medium- and 
long-term outpatient intravenous therapy in a ter-
tiary care university hospital, with the support of a 
multidisciplinary team (including an interventional 
radiologist, oncologist, infection prevention expert, 
infectious disease physician and nurse practitioners 
experienced with venous access devices). 
In our hospital, a previous attempt to introduce 
PICCs was aborted in 2012 after an unsystematic 
approach, seemingly accompanied by high rates of 
complications. We hypothesised that support from 
the infection prevention team in the form of struc-
tured surveillance for infectious and noninfectious 
complications could provide quality indicators to 
assure patient safety during the implementation 
phase of this vascular access new to our hospital. 
Material and methods 
We conducted a prospective surveillance study at 
our 950-bed academic hospital (Bern University 
Hospital, Bern, Switzerland), collecting data of all 
patients from the oncology and infectious diseases 
departments who underwent PICC insertion from 1 
January 2014 on and had the catheter removed by 
31 December 2015. Since our study was a quality 
assessment project, ethical approval was not re-
quired. 
All patients requiring intravenous therapy for more 
than 7 days primarily in the outpatient setting, ac-
cording to the decision of the treating oncologist or 
infectious diseases specialist, were eligible for in-
clusion. All patients were followed during the PICC 
placement time irrespective of the management set-
ting (outpatient, inpatient, intermittently hospital-
ised after insertion). The primary author (ELP) col-
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lected data by manual review of each patient’s elec-
tronic medical record, from the catheter booklet and 
by contacting both the hospital-based and home care 
nursing teams. The following patient data were col-
lected: demographic characteristics; cancer type, or-
gan and stage; nononcological diagnosis; body mass 
index (BMI) and Charlson comorbidity score [22]. 
Catheter information included date, site of insertion, 
number of lumen, clinical indication, infused drugs, 
total days in place and reason for removal. The date 
of catheter insertion was defined as day one. In our 
analysis, we included only major complications, 
which are defined and listed below. Educational ses-
sions were offered to the hospital-based (infection 
prevention team and vascular access team) and 
community-based (home care nurse) nursing ser-
vices under the lead of a nurse practitioner (M.F.). 
Our primary goal was to measure the incidence rate 
of central catheter-associated infections expressed 
in events per 1000 catheter-days, defined according 
to the Centers for Disease Control and Prevention 
(CDC) / National Healthcare Safety Network 
(NHSN) definition [11, 12]. For the definition of 
central catheter-associated bloodstream infection, 
both laboratory-confirmed bloodstream infection 
(LCBI) and the recently added subcategory mucosal 
barrier injury laboratory-confirmed bloodstream in-
fection (MBI-LCBI) were used. Exit-site infection 
was diagnosed according to the CDC/NHSN sur-
veillance definitions for arterial or venous infection 
(VASC). 
The occurrence of the following noninfectious com-
plications was a secondary endpoint: catheter re-
lated-venous thrombosis, catheter tip migration, 
catheter occlusion and mechanical complications 
(catheter rupture, haemothorax, pneumothorax, car-
diac tamponade or arrhythmia). For the diagnosis of 
venous thrombosis and tip migration, clinical symp-
toms had to be confirmed radiologically (ultra-
sound, venography or computed tomography). 
Catheter occlusion was defined as the inability to 
flush and/or withdraw blood. Other noninfectious 
complications were determined from the diagnoses 
made by the treating physician. Each complication 
that occurred during catheterisation was counted as 
a separate event. 
The introduction of PICCs was planned in two 
phases: during phase one (January 2014 to June 
2014) only cancer patients fulfilling the inclusion 
criteria were eligible for PICC insertion; during 
phase two (July 2014 to December 2015) the indi-
cation was extended to infectious diseases patients. 
A single lumen polyurethane 4F catheter (PRO-
PICC® CT, medCOMP, Harleysville, PA, USA) 
was chosen to be the standard for all patients. Before 
catheter insertion, all patients gave their informed 
consent. All catheters were placed under maximum 
sterile barrier precautions by an interventional radi-
ologist. The dedicated team consisted of three sen-
ior interventional radiologists, who gradually 
trained a team of junior physicians. For skin anti-
sepsis, 2% chlorhexidine-alcohol solution was used. 
The selection of the insertion site and vein to can-
nulate was based on patient preference and vascular 
anatomy. Veins were cannulated under sonographic 
guidance; subsequent catheter insertion and tip lo-
calisation were evaluated under fluoroscopic guid-
ance. The use of venography was restricted to se-
lected cases. After insertion, the catheter was fixed 
using a suture-free device (STATLOCK® stabilisa-
tion device, BardMedical®, Louisville, CO, USA) 
and the exit site covered with a transparent dressing 
and sterile gauze (to obtain light compression in or-
der to reduce the risk of initial bleeding at the inser-
tion site). Within the next 24 hours, the preliminary 
dressing was replaced with a chlorhexidine gel pad 
dressing (TEGADERM CTH®, 3M, St. Paul, MN, 
USA) and thereafter changed every 7 days (or 
sooner if damp, loose or visibly soiled). Only 
trained personnel were allowed to manipulate the 
catheters. As a general rule, the catheter hub was al-
ways disinfected before handling. Catheter patency 
was tested before each use. The catheter was flushed 
by exerting intermittent pressure with a 0.9% saline 
solution before and after each use. Following use, 
the catheter was locked with a heparin solution (200 
IU). Every patient received a PICC handbook to 
document any procedure done at home or in the hos-
pital. The catheter care protocol and material used 
by the home nursing team differed from those used 
by the hospital nursing team. The main differences 
consisted of the following elements: suture-free de-
vice (GRIP-LOK®, TIDI products®, Neenah, WI, 
USA); use of a silver alginate pad instead of a chlor-
hexidine gel pad, catheter lock with citrate prefilled 
syringes (Dura Lock®, medComp®, Harleysville, 
PA, USA), and a different needleless device 
(NeutraClear®, ICUmedical®, San Clemente, CA, 
USA). Neither antibiotics nor antithrombotic 
prophylaxis was routinely administered. 
Statistical analysis 
Data were collected into an Excel electronic data-
base (Microsoft Corporation, Seattle, WA). The 
study population was characterised by use of de-
scriptive statistics. SPSS 21.0 (SPSS, Inc., an IBM 
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Company, Chicago, IL) was used for all statistical 
analyses. Time to PICC removal was evaluated with 
a Kaplan–Meier curve to estimate the cumulative 
probability that the catheter would still be in place 
at any time since placement. Data were censored at 
the time of catheter removal. 
Results 
Population data 
Between 1 January 2014 and 31 December 2015, a 
total of 135 catheters where inserted into 124 pa-
tients. The median age of the patients was 60.5 
years; the majority were female (n = 70, 56.5%). 
Oncological patients prevailed (n = 107, 86.3%); 
most of them were affected by solid tumours (n = 
72, 67.3%). Further patient characteristics are listed 
in table 1.  
 
Table 1: Characteristics of the 124 patients within the PICC 
pilot programme. 
Total, n (%) 124 (100) 
Female, n (%) 70 (56.5) 
Age, median (range) 60.5 (15-85) 
BMI, median (range) 25.3 (16-52) 
CCI, median (range) 2 (0-11) 
Underlying condition, n (%)  
Cancer 107 (86.3) 
Haematological malignancies 34 (31.8) 
Solid tumours 73 (68.2) 
Stage  
<III 23 (31.5) 
III 50 (68.5) 
Noncancer 17 (13.7) 
Orthopaedic SSI 9 (52.9) 
Osteomyelitis 2 (11.7) 
Brain abscess 2 (11.7) 
Endocarditis 1 (5.9) 
Abdominal SSI 1 (5.9) 
Lower airways infection 1 (5.9) 
Total parenteral nutrition 1 (5.9) 
Primary indication for PICC, n (%)  
Chemotherapy 97 (71.9) 
Intravenous antibiotics 24 (17.8) 
Total parenteral nutrition 8 (5.9) 
Blood products transfusion 4 (3.0) 
Palliative care 2 (1.5) 
BMI = body mass index; CCI = Charlson comorbidity score; PICC = 
peripherally inserted central catheter; SSI = surgical site infection 
Overall, the indications for PICC insertion were 
chemotherapy (n = 97, 71.9%), antibiotic therapy (n 
= 24, 17.8%), total parenteral nutrition (n = 8, 
5.9%), blood product transfusion (n = 4, 3.0%) and 
palliative care (n = 2, 1.5%). 
The 135 PICCs were in place for a total of 10 402 
catheter-days, with a median dwell time of 62 days 
(range 2–450 days) and all were monitored until re-
moval. Catheter dwell time was longer when the 
PICC indication was chemotherapy (median 80, 
range 2-450). Additional PICC characteristics are 
listed in table 2.  
 
Table 2: Catheter data for the 135 devices inserted during 
the peripherally inserted central catheter (PICC) pilot pro-
gramme. 
PICC characteristic, n (%) 
 
Total 135 (100) 
Number of lumens  
1 132 (97.8) 
2 2 (1.5) 
3 1 (0.7) 
Arm  
Left 101 (74.8) 
Right 34 (25.2) 
Vein  
Basilic vein 109 (80.7) 
Brachial vein 23 (17.0) 
Cephalic vein 1 (0.7) 
Median vein 1 (0.7) 
Femoral vein 1 (0.7) 
Catheter-days, total 10 402 
Catheter-days, median (range) 62 (2–450) 
Dwell time by indication (days), median 
(range) 
 
Chemotherapy 80 (2–450) 
Intravenous antibiotics 31 (8–87) 
Total parenteral nutrition 71 (3–160) 
Blood products transfusion 29 (18–60) 
Palliative care 10 (8–11) 
Reason for removal, n (%)  
End of treatment 86 (63.7) 
PICC-unrelated death 18 (13.3) 
Other 9 (6.7) 
PICC-associated infection 7 (5.2) 
PICC tip migration 7 (5.2) 
Suspected PICC-associated infection 5 (3.7) 
PICC-associated venous thrombosis 2 (1.5) 
PICC occlusion 1 (0.7) 
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Figure 1: Incidence rate of central line-associated bloodstream infections (CLABSIs) per catheter-days per month. 
 
We followed up patients in any healthcare setting, 
including ambulatory and in-hospital care. Of the 
124 patients, 62 (50%) were hospitalised for at least 
24 hours during the observation period. Fifty-five 
patients (44.4%) were managed in the outpatient 
setting only and seven were managed solely as in-
patients (5.6%). None of the patients were hospital-
ised in an ICU. 
Outcomes 
Five CLABSIs occurred in five cancer patients, 
yielding an incidence rate of 0.48 per 1000 catheter-
days. In figure 1, the overall incidence rates of 
CLABSI that occurred are displayed with total 
monthly catheter-days. One episode fulfilled the cri-
teria for an MBI-LCBI (in a haemato-oncology pa-
tient with chemotherapy-induced neutropenia). Two 
CLABSIs where caused by coagulase-negative 
staphylococci and occurred 11 and 14 days after 
catheter insertion, respectively. Another two were 
caused by Enterobacter cloacae and occurred 114 
and 119 days after insertion. The episode of MBI-
LCBI was also caused by Enterobacter cloacae and 
occurred 29 days after catheter insertion. Two exit-
site infections occurred, both identified by the pres-
ence of purulent exudate (no exit site swab was 
taken). All catheter-related infections resulted in 
PICC removal (n = 7; 5.2%). There were five (3.7%) 
additional cases of suspected catheter-related infec-
tion, for which the catheter was removed although 
the epidemiological definition was not fulfilled. 
Seven radiologically confirmed venous thromboses 
occurred in seven patients (six of them were cancer 
patients: four lymphomas, one testicular cancer and 
one ovarian cancer), accounting for a rate of 0.68 
per 1000 catheter-days. All thromboses affected the 
upper extremity where the catheter was inserted, 
four in the deep venous system and three in the su-
perficial venous system, and in two cases led to 
catheter removal because of an associated catheter 
dysfunction. Ten episodes of catheter tip migration 
occurred in ten patients, and resulted in PICC re-
moval in seven cases. 
The most frequent complication was catheter flow 
dysfunction (not related to the above-cited compli-
cations) and occurred in 22 separate episodes. In 
seven patients, it was due to device occlusion, which 
yields an incidence rate of 0.68 per 1000 catheter-
days. In 18 of 22 cases the flow could be success-
fully re-established by use of an alteplase lock. In 
one case, the catheter had to be removed owing to 
irreversible occlusion, and in the three remaining 
cases the flow dysfunction spontaneously resolved 
without further intervention. Overall, at the end of 
the surveillance period, 46 complications had oc-
curred, with a rate of 4.5 per 1000 catheter-days.  
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Seventeen catheters (12.6%) had to be removed be-
cause of a complication.   
The catheter survival data according to the time of 
onset of complication for the four major complica-
tions that required catheter removal (infection, 
thrombosis, tip migration and occlusion) are shown 
in figure 2. Only one periprocedural complication 
occurred: significant bleeding at the insertion site in 
a patient with thrombopenia and concurrent medi-
cation with the antiplatelet agent clopidogrel. 
Discussion 
PICCs are an established and safe alternative to cen-
tral venous catheters inserted into the jugular or sub-
clavian vein for medium- and long-term intravenous 
therapy [16, 23]; our surveillance data provide ad-
ditional support in favour of their use. To assure 
maximum quality of care and patient safety, it is es-
sential to collect and utilise quality indicators in or-
der to assess complications [24]. The overall com-
plication rate we encountered in this study was low, 
taking into account the heterogeneous patient popu-
lation with a high proportion of oncological pa-
tients. Cancer patients, especially those with haema-
tological malignancies, are notable for being at in-
creased risk for catheter-related complications [6, 
13, 15, 25]. Our CLABSI rate was comparable to 
the rate in a recent study that included a similar pa-
tient population and care setting, with a reported 
CLABSI rate of 0.95 per 1000 catheter days [26]. 
However, another recent study showed a low blood-
stream infection rate when PICCs were used in the 
outpatient setting in a cancer patient population, 
with a catheter-related bloodstream infection 
(CRBSI) rate as low as 0.05 per 1000 catheter-days 
[16]. This low infection rate should be cautiously 
compared to ours since a different definition 
(CRBSI), which included additional microbiologi-
cal information (quantitative culture and time to 
positivity), was used. In fact, it is well known that 
the CLABSI definition tends to overestimate the 
real number of catheter-related infections [27], and 
although CRBSI is more clinically accurate, 
CLABSI is more suitable for surveillance purposes 
[28]. A meta-analysis by Chopra et al. comparing 
PICC to other central venous access devices sup-
ported the fact that the former was associated with a 
lower risk of CLABSI in ambulatory settings. In our 
cohort, five catheters were removed for suspected 
infection, the decision for which was taken by the 
treating physician. The appropriate indication for 
catheter removal should be based on the clinical 
condition (e.g., sepsis, thrombophlebitis) and mi-
crobiology results (e.g., Staphylococcus aureus, 
Gram-negative bacilli, fungi) as highlighted in the 
2009 guideline of the Infectious Disease Society of 
America [29]. 
The rate of thrombosis we encountered was higher 
than previously reported for central venous cathe-
ters in cancer patients, as shown by Lee et al. (0.3 
per 1000 catheter days). Nevertheless, wide differ-
ences in similar patient populations, ranging from 
0.05 to 0.95 per 1000 catheter days, were demon-
strated in two recent studies [16, 26]. A possible ex-
planation for our findings was the inclusion of pa-
tients with lymphoma and ovarian cancer, who are 
known to be at increased risk for thrombosis [30, 
 
Figure 2: Kaplan-Meier curve of 
catheter survival based on the 
occurrence of complications 
that led to catheter removal. 
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31] and who represented five out of the six cancer 
patients with a catheter-related thrombosis. Another 
potential risk factor could have been hospitalisation 
during follow-up [32] 
The multidisciplinary nature of the study team, a 
characteristic shown to have an effect on complica-
tion rates in other centres as reported by Curto-Gar-
cia et al. [17], ensured the needed broad support and 
sustained acceptance in our hospital, and, in our 
opinion, has to be considered as the central element 
in all institutions wishing to introduce new vascular 
devices and to include hospital-based and commu-
nity-based healthcare personnel. In their surveil-
lance study, the authors saw PICC-related compli-
cations decrease in patients with haematological 
malignancies receiving intensive chemotherapy af-
ter a multidisciplinary team had been charged with 
establishing evidence-based guidelines and educa-
tion programmes. The team consisted of two hae-
matologists, one medical microbiologist, three hae-
matology nurses, one ICU nurse and one emergency 
department nurse. 
The establishment of evidence-based guidelines for 
the introduction of the new vascular access high-
lights the importance of implementation science in 
promoting the integration of evidence-based find-
ings into daily clinical practice. In fact, evidence-
based data summaries for central venous catheter in-
sertion and maintenance care have been confirmed 
to be an efficacious measure in preventing CLABSI, 
as recently documented in a meta-analysis by Ista et 
al. [33]. The efficacy of such interventions has pri-
marily been demonstrated in the ICU setting [34], 
whereas there is currently weak evidence regarding 
catheters outside the ICU [35]. In our study, the in-
fection prevention team provided an objective eval-
uation of how PICCs perform by monitoring essen-
tial quality indicators during the entire process, 
which were reviewed by the interdisciplinary team 
on a regular basis. Infectious complications repre-
sented only 15% of the adverse events seen in our 
population, indicating that a substantial effort 
should be directed at the prevention of noninfec-
tious complications during the implementation of 
PICCs. More evidence for the prevention of the lat-
ter complication group needs to be accrued to estab-
lish guidelines supporting clinical decision making. 
We noticed that the two CLABSI associated with 
Gram-positive bacteria occurred rather early after 
insertion, in contrast to a later presentation of Gram-
negative bacteria-associated CLABSI. The single 
MBI-LCBSI also occurred relatively early (in the 
first month); a similar finding was previously re-
ported by a study in a paediatric population [36]. In 
contrast, a retrospective study in adults showed that 
coagulase-negative staphylococci and Enterobacte-
riaceae were typical pathogen groups associated 
with CLABSI throughout catheter dwell time [37]. 
The event numbers in our cohort were too small to 
further elucidate this aspect. 
Study limitations included the presence of a hetero-
geneous population in different management set-
tings and various protocols of care that limited more 
specific analysis; however, these questions were out 
of the scope of our study. Interpretation of the re-
ported infection rate should take into account that 
additional preventive measures were used through-
out the implementation phase (such as chlorhexi-
dine dressing and silver alginate). Despite the fact 
that chlorhexidine dressing and silver alginate are 
second-line measures to prevent CLABSI [24], we 
decided to introduce chlorhexidine gel pads as a tool 
to reduce the risk of infectious adverse events [38] 
that could have led to an early project failure. The 
single-centre design cannot guarantee the generali-
sability of the processes of care to other settings. We 
could also have missed certain complication events 
if a patient was hospitalised in another region of 
Switzerland (despite the regular checks of the pa-
tient’s catheter booklet). Since the vast majority 
(97.8%) of the PICCs were single lumen catheters 
we cannot extrapolate these encouraging results to 
multilumen PICCs. 
The strength of our study includes the prospective 
multidisciplinary design and the use of clear epide-
miological definitions for catheter-related infec-
tions and clear clinical definitions for noninfectious 
complications. Our findings could help facilities 
willing to introduce PICCs to decide in favour of 
early involvement of the infection prevention team 
during the implementation of a new device. The 
strategy presented here could also easily be ex-
tended to other intravascular devices. The efficacy 
of this approach has recently been highlighted in the 
study of Kim-Saechao et al. [39], where the imple-
mentation of a mandatory electronic communica-
tion tool overseen by multidisciplinary leadership, 
which included the infection control team, resulted 
in a decreased rate of PICC-related complications. 
Conclusion 
We introduced PICCs in an academic hospital by 
implementing a surveillance programme for com-
plications. Both infectious and noninfectious com-
plications were rare. Infection prevention specialists 
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should be actively involved during the introduction 
of new intravascular devices in order to provide 
quality indicators and assure patient safety 
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